Week 3: With over 3,000 GPTs deployed, Moderna is actively redesigning teams and making staffing decisions based on AI's capabilities.

Moderna, a pioneering biotech company, is at the forefront of an AI-driven workplace transformation, leveraging a deep partnership with OpenAI. This collaboration has led to the development of thousands of customized AI models, or GPTs, aimed at automating tasks previously performed by human employees, significantly impacting the company's operational structure. This strategic shift highlights a bold move towards integrating artificial intelligence into the core of pharmaceutical development and corporate functions.

The partnership, initiated in 2023 with an internal employee chatbot, expanded significantly in April 2024, granting Moderna employees access to ChatGPT Enterprise. This platform empowers users to create specialized GPTs, like the successful Dose ID GPT, which efficiently evaluates optimal vaccine doses by analyzing vast amounts of data. These AI assistants are now deeply embedded across all business functions, from research and manufacturing to legal and commercial, augmenting human roles with personalized support. With over 3,000 GPTs deployed, Moderna is actively redesigning teams and making staffing decisions based on AI's capabilities. This includes merging HR and Tech departments under a single leader, Chief People and Digital Technology Officer Tracey Franklin, who is reimagining roles and workflows. While this transformation promises enhanced efficiency and accelerated life-saving treatments, the company's recent layoffs in its digital technology division indicate the complex implications of extensive AI adoption on human capital. 

Sherry, B. (n.d.). Why vaccine maker Moderna is injecting AI across the company. Inc.com. https://www.inc.com/ben-sherry/why-vaccine-maker-moderna-is-injecting-ai-across-the-company/91188434 #Moderna, #AI, #Biotech, #Workplace, #Innovation